

BLADDER CANCER



# Know cancer's next move

with personalized, tumor-informed molecular residual disease (MRD) detection for muscle invasive bladder cancer (MIBC)




Covered by Medicare

### Inform critical decisions in MIBC




### Identify patients at risk of relapse who may benefit from adjuvant therapy and monitor response to immunotherapy 1,3-5



## Aarhus University Study: Signatera<sup>™</sup> status at all assessed timepoints was highly prognostic of patient outcomes<sup>3</sup>

68 locally advanced MIBC patients with 656 plasma samples collected longitudinally with a median follow-up of 21 months



×

×


XX

 $\times$   $\times$   $\times$   $\times$ 

#### **IMvigor010:** Signatera<sup>™</sup> positivity after a single timepoint post-cystectomy may predict who will benefit from adjuvant immunotherapy treatment<sup>1,4</sup>



Phase III, randomized clinical trial of atezolizumab vs observation in high-risk adjuvant MIBC



+

× ×

× ×

> × × ×


×

 $\mathbf{X}$ × X

- ctDNA-positive patients had a significant survival benefit when treated with atezolizumab (OS, HR = 0.59).<sup>4</sup>
- No treatment benefit was observed in ctDNA-negative patients treated with atezolizumab (OS, HR = 1.38).4
- > >75% of patients with detectable ctDNA post-surgery in the observation arm recurred by 20 month follow up.<sup>1</sup>

#### **IMvigor011 (ongoing):** Patients who remain serially Signatera<sup>™</sup> negative post-cystectomy may be spared adjuvant therapy, underscoring the value of longitudinal monitoring<sup>6</sup>

Phase III, randomized double-blind study evaluating the efficacy of atezolizumab in patients with high-risk MIBC who are ctDNA-positive post-cystectomy




Signatera<sup>™</sup> is covered by Medicare and a growing number of commercial payers for monitoring patients with MIBC as well as any patient being treated with immunotherapy



## **Real world case study:** 60 year old male with MIBC and persistently positive Signatera<sup>™</sup> ctDNA

#### **Historical results**



Case features modified to protect patient confidentiality. No treatment recommendations are made or should be implied.

#### The most comprehensively validated MRD assay



#### Extensively validated

Signatera<sup>™</sup> has been validated in >65 peer-reviewed publications studying >6,500 patients across >25 tumor types<sup>7</sup>

$\sim$	

#### **Deep experience**

Scan here to learn more

Signatera<sup>™</sup> has been used to manage over **175,000** patients and has been ordered by **more than 1/3** of US oncologists<sup>7</sup>

## Signatera<sup>™</sup> can be run at any time point on the core biopsy or surgical resection and is covered by Medicare and a growing number of commercial payers for MIBC patients and any patient being treated with immunotherapy

#### Learn more about Natera's Oncology Portfolio:

Empower™ Hereditary cancer test Empower<sup>™</sup> for hereditary cancer testing which analyzes up to 81 genes across 12+ common hereditary cancers (panel can also be customizable, up to 190 genes) to help guide surgical and therapeutic decisions.)

Altera<sup>™</sup> Tumor genomic pro Add on Altera<sup>™</sup> Genomic Profiling test which utilizes whole-exome and whole-transcriptome sequencing to identify clinically relevant biomarkers that may help guide treatment selection for advanced cancer patients– no additional sample needed.

#### References

- 1. Powles T, et al. Nature. 2021;595(7867):432-437. https://doi.org/10.1038/s41586-021-03642-9.
- Svatek RS, et al. Can Urol Assoc J. 2009. doi: 10.5489/cuaj.1203.
  Christensen E, et al. J Clin Oncol. 2019. doi: 10.1200/JCO.18.02052.
- Christensen E, et al. J Clin Oncol. 2019. doi: 10.1200/JCO.18.02052.
  Powles T, et al. European Urology. 2023; https://doi.org/10.1016/j.eururo.2023.06.007.
- Powles I, et al. European Urology. 2023; https://doi.org/10.1016/j.eururo.2023.0t
  Bratman SV et al. Nature Cancer. 2020;1(9):873-881
- Bratman SV, et al. *Nature Cancer.* 2020;1(9):873-881.
  Powles T, et al Presented at EAU annual conference, 2024.
- Natera Data on File as of May 1st, 2024.

#### 13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | www.natera.com

Signatera<sup>™</sup> has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. Results obtained are specific to the assessed time point. A negative test result does not definitively indicate the absence of cancer. © 2024 Natera, Inc. All Rights Reserved. SGN\_BR\_MIBC\_20240510\_NAT-8021622



屠 natera

